Keywords: American Diabetes Association, Novo Nordisk, Victoza, Degludec, Sanofi, Lyxumia, Eli Lilly, Boehringer Ingelheim, Tradjenta, Empagliflozin
Highlights of American Diabetes Association meeting
Article | 11 June 2012
The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented at the 72nd ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
